" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

NCT05580510 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Congenital Heart Disease
Heart Failure
Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
DRUG: Empagliflozin 10 MG OD

Sponsor

Instituto Nacional de Cardiologia Ignacio Chavez

Collaborators

[object Object]